Shortening of interestrous intervals with cabergoline in bitches: a clinical trial.
Two consecutive interestrous intervals (n=46) were recorded in 23 bitches of different breeds. At varying times after day 100 from the onset of the second proestrus, cabergoline (5 microg/kg per os q 24 hours) was administered from early (n=11), mid- (n=10), and late (n=2) anestrus until 2 days after the beginning of the following proestrus. Interestrous intervals (IEI) were significantly shorter in the cabergoline-treated time periods when compared to the nontreated IEI (184+/-4.5 days versus 239+/-4.5 days; P<0.01). The mean number of days of cabergoline treatment until the onset of proestrus was 21.4+/-2.9 (least square means and standard error of the mean [LSM+/-SEM]). Mean cabergoline treatment durations beginning in early, mid-, and late anestrus were 27.4+/-3.7, 17.6+/-3.8, and 5+/-3 days (LSM+/-SEM), respectively. A significant correlation was found between the stage of anestrus in which the treatments began and the duration of the treatments required to induce estrus (0.51, P=0.01).
Gobello
Cristina
C
Small Animal Clinic and Animal Reproduction, Faculty of Veterinary Medicine, National University of La Plata, La Plata, Argentina.
Castex
Gervasio
G
Dela sota
Luzbel
L
Corrada
Yanina
Y
D000780:Anestrus / Q000097:blood / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D001947:Breeding; D000077465:Cabergoline; D004285:Dogs / Q000097:blood / Q000502:physiology*; D018491:Dopamine Agonists / Q000097:blood / Q000494:pharmacology*; D004873:Ergolines / Q000097:blood / Q000494:pharmacology*; D004971:Estrus / Q000097:blood / Q000187:drug effects* / Q000502:physiology; D005260:Female; D011374:Progesterone / Q000097:blood; D013997:Time Factors; D014621:Vagina / Q000166:cytology
D018491:Dopamine Agonists; D004873:Ergolines; D011374:Progesterone; D000077465:Cabergoline